Unicycive Therapeutics IncUnicycive Therapeutics Inc
Unicycive Therapeutics Inc

Unicycive Therapeutics Inc

UNCY
Health Care·Biotechnology

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

California; U.S.A
Market cap
$113.1MNo data
Revenue
No dataNo data
Net income
$-26.6M+27.7% YoY
Free cash flow
$-31.3M−9.4% YoY

Market

Listed stock
UNCYPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
No dataNo data
Operating income
$-29.5M+8.1% YoY
Net income
$-26.6M+27.7% YoY
Free cash flow
$-31.3M−9.4% YoY

Revenue, profit & cash trend

Revenue
Reference
Revenue: 2021 $0, 2022 $951K, 2023 $675K, 2024 $0. Reference line: Reference at $0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $-9M, 2022-12-31 $-18.1M, 2023-12-31 $-20.8M, 2024-12-31 $-32.1M, 2025-12-31 $-29.5M. Net income: 2021-12-31 $-10M, 2022-12-31 $-18.1M, 2023-12-31 $-30.5M, 2024-12-31 $-36.7M, 2025-12-31 $-26.6M. Free cash flow: 2021-12-31 $-5.8M, 2022-12-31 $-15.7M, 2023-12-31 $-18.3M, 2024-12-31 $-28.6M, 2025-12-31 $-31.3M

Growth heatmap

202220232024CAGR
Revenue
No data
-29.0%
-100.0%
No data
Gross profit
No data
-29.0%
-100.0%
No data
Operating income
-101.1%
-15.1%
-54.6%
+8.1%
No data
Free cash flow
-171.4%
-16.9%
-56.6%
-9.4%
No data

Earnings quality

Operating cash flow
$-31.3M−9.6% YoY
Net income
$-26.6M+27.7% YoY
Free cash flow
$-31.3M−9.4% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 118%, 2024-12-31 78%, 2023-12-31 60%, 2022-12-31 87%, 2021-12-31 58%. Free cash flow: 2025-12-31 118%, 2024-12-31 78%, 2023-12-31 60%, 2022-12-31 87%, 2021-12-31 58%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data